Welcome to the international HTA database

Showing [23806 Records] Selected Records [0 Hits] [Clear]

Year	Source	Title
2014	HAYES, Inc.	Intravenous iron for the treatment of iron deficiency with or without anemia in patients with chronic heart failure
2014	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Paclitaxel albumin-bound nanoparticles (Abraxane®)
2014	Canadian Agency for Drugs and Technologies in Health (CADTH)	Treatments for patients with genotype 1 chronic hepatitis C: a review of evidence-based guidelines
2014	NIHR Health Technology Assessment programme	Dexamethasone intravitreal implant for treating diabetic macular oedema [ID653]
2014	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Idelalisib - Benefit assessment according to §35a Social Code Book V (dossier assessment)]
2014	National Institute for Health and Care Excellence (NICE)	Implantable cardioverter defibrillators and cardiac resynchronisation therapy for arrhythmias and heart failure. NICE technology appraisal guidance 314
2014	National Institute for Health and Care Excellence (NICE)	Endoscopic thoracic sympathectomy for primary facial blushing. NICE interventional procedures guidance 480
2014	NIHR Horizon Scanning Centre (NIHR HSC)	Palbociclib for advanced ER-positive/HER2-negative breast cancer in post-menopausal women – first line in combination with letrozole
2014	HAYES, Inc.	Ligament Augmentation and Reconstruction System (LARS) for ligament repairs of the knee
2014	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Certolizumab pegol (Cimzia®)
2014	Canadian Agency for Drugs and Technologies in Health (CADTH)	Automated notification and reminder call systems: guidelines
2014	NIHR Health Technology Assessment programme	Vedolizumab for treating moderate to severe active Crohn's disease after prior therapy [ID690]
2014	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Albiglutide - Benefit assessment according to §35a Social Code Book V (dossier assessment)]
2014	National Institute for Health and Care Excellence (NICE)	Canagliflozin in combination therapy for treating type 2 diabetes. NICE technology appraisal guidance 315
2014	National Institute for Health and Care Excellence (NICE)	Insertion of prostatic urethral lift implants to treat lower urinary tract symptoms secondary to benign prostatic hyperplasia. NICE interventional procedures guidance 475
2014	NIHR Horizon Scanning Centre (NIHR HSC)	Rigosertib for higher risk myelodysplastic syndromes – second and subsequent line
2014	HAYES, Inc.	Preoperative physical therapy for severe osteoarthritis of the hip
2014	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Bortezomib (Velcade®)
2014	Canadian Agency for Drugs and Technologies in Health (CADTH)	Administration of naloxone in a home or community setting: a review of the clinical effectiveness, cost-effectiveness, and guidelines
2014	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Sipuleucel-T - Benefit assessment according to §35a Social Code Book V (dossier assessment)]
2014	National Institute for Health and Care Excellence (NICE)	Enzalutamide for metastatic hormone-relapsed prostate cancer previously treated with a docetaxel-containing regimen. NICE technology appraisal guidance 316
2014	National Institute for Health and Care Excellence (NICE)	Transcranial magnetic stimulation for treating and preventing migraine. NICE interventional procedures guidance 477
2014	NIHR Horizon Scanning Centre (NIHR HSC)	Sunitinib malate (Sutent) for renal cell carcinoma – adjuvant therapy
2014	HAYES, Inc.	Reverse shoulder total joint prosthesis
2014	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Certolizumab pegol (Cimzia®) [in combination with methotrexate]
2014	Canadian Agency for Drugs and Technologies in Health (CADTH)	Continuous positive airway pressure for acute respiratory failure in the pre-hospital setting: guidelines
2014	National Institute for Health and Care Excellence (NICE)	Prasugrel with percutaneous coronary intervention for treating acute coronary syndromes. NICE technology appraisal guidance 317
2014	National Institute for Health and Care Excellence (NICE)	Arthroscopic trochleoplasty for patellar instability. NICE interventional procedures guidance 474
2014	NIHR Horizon Scanning Centre (NIHR HSC)	Minicare H-2000 remote monitoring system for patients undergoing chemotherapy
2014	HAYES, Inc.	Revisional surgery for treatment of complications after bariatric surgery
2014	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Alogliptin (Vipidia®)
2014	Canadian Agency for Drugs and Technologies in Health (CADTH)	Long-term 5HT3 antagonist use for alcohol dependence: clinical evidence and guidelines
2014	Malaysian Health Technology Assessment (MaHTAS)	Rapid blood test device for HIV, HBV, HCV, & syphillis
2014	National Institute for Health and Care Excellence (NICE)	Ipilimumab for previously untreated advanced (unresectable or metastatic) melanoma. NICE technology appraisal guidance 319
2014	National Institute for Health and Care Excellence (NICE)	Radiofrequency ablation of the soft palate for snoring. NICE interventional procedures guidance 476
2014	NIHR Health Technology Assessment programme	The 3Mg Trial: Randomised controlled trial of intravenous or nebulised magnesium sulphate or standard therapy for acute severe asthma
2014	NIHR Horizon Scanning Centre (NIHR HSC)	Ciclosporin (CicloMulsion) for reperfusion injury prevention prior to percutaneous coronary intervention for ST-segment elevation acute myocardial infarction
2014	HAYES, Inc.	Roux-en-Y gastric bypass for diabetes in obese or severely obese patients
2014	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Alogliptin/metformin (Vipdomet®)
2014	Canadian Agency for Drugs and Technologies in Health (CADTH)	Management of massive blood transfusion in the rural setting: guidelines
2014	Malaysian Health Technology Assessment (MaHTAS)	Ultrasonic wound debridement device
2014	National Institute for Health and Care Excellence (NICE)	Dimethyl fumarate for treating relapsing–remitting multiple sclerosis. NICE technology appraisal guidance 320
2014	NIHR Horizon Scanning Centre (NIHR HSC)	Recombinant human alpha-mannosidase (Lamazym) for alpha mannosidosis
2014	HAYES, Inc.	Second-wave direct-acting antivirals for hepatitis C: Simeprevir
2014	Belgian Health Care Knowledge Centre (KCE)	Caring for mothers and newborns after uncomplicated delivery: towards integrated postnatal care
2014	Canadian Agency for Drugs and Technologies in Health (CADTH)	Cryotherapy systems for wart removal: a review of the clinical effectiveness, cost-effectiveness, and guidelines
2014	Malaysian Health Technology Assessment (MaHTAS)	Pulse oximetry screening for critical congenital heart disease in newborn infants
2014	National Institute for Health and Care Excellence (NICE)	Dabrafenib for treating unresectable or metastatic BRAF V600 mutation positive melanoma. NICE technology appraisal guidance 321
2014	NIHR Health Technology Assessment programme	A modelled analysis using data from the ARTISTIC trial of the potential effectiveness and cost-effectiveness of HPV testing in cervical cancer screening
2014	NIHR Horizon Scanning Centre (NIHR HSC)	Metreleptin for generalised and partial lipodystrophy
2014	HAYES, Inc.	Second-wave direct-acting antivirals for hepatitis C: Sofosbuvir and Ledipasvir
2014	Belgian Health Care Knowledge Centre (KCE)	Management of autism in children and young people: a good clinical practice guideline
2014	Canadian Agency for Drugs and Technologies in Health (CADTH)	Jewellery and the risk of bacteria transmission from healthcare worker to patient: clinical evidence
2014	Malaysian Health Technology Assessment (MaHTAS)	Piston-type mechanical chest compression
2014	National Institute for Health and Care Excellence (NICE)	Lenalidomide for treating myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality. NICE technology appraisal guidance 322
2014	NIHR Health Technology Assessment programme	T-DM1 for treating HER2-positive, unresectable locally advanced or metastatic breast cancer after treatment with trastuzumab and a taxane
2014	NIHR Horizon Scanning Centre (NIHR HSC)	myVisionTrack® for monitoring degenerative eye disease
2014	HAYES, Inc.	ß-D-glucan assay for detection of invasive fungal disease
2014	NIHR Health Technology Assessment programme	The use of fenestrated and branched endovascular aneurysm repair for juxtarenal and thoracoabdominal aneurysms: a systematic review and cost-effectiveness analysis
2014	Canadian Agency for Drugs and Technologies in Health (CADTH)	Intranasal versus intravenous naloxone for opioid overdose in the pre-hospital setting: comparative clinical effectiveness
2014	National Institute for Health and Care Excellence (NICE)	Erythropoiesis stimulating agents (epoetin and darbepoetin) for treating anaemia in people with cancer having chemotherapy. NICE technology appraisal guidance 323
2014	NIHR Horizon Scanning Centre (NIHR HSC)	Tabalumab for systemic lupus erythematosus
2014	HAYES, Inc.	Ultrasound-guided injections of joints of the extremities
2014	NIHR Health Services and Delivery Research programme	Organisational interventions to reduce length of stay in hospital: a rapid evidence assessment
2014	Canadian Agency for Drugs and Technologies in Health (CADTH)	Intrathecal bupivacaine via infusion pump for the management of pain: clinical evidence, safety, and guidelines
2014	HTA Unit, University of Calgary	Repetitive transcranial magnetic stimulation for treatment resistant depression
2014	Malaysian Health Technology Assessment (MaHTAS)	Inexscreen as a screening test for ectopic pregnancy and miscarriage
2014	National Institute for Health and Care Excellence (NICE)	Dual-chamber pacemakers for symptomatic bradycardia due to sick sinus syndrome without atrioventricular block. NICE technology appraisal guidance 324
2014	NIHR Horizon Scanning Centre (NIHR HSC)	SafePlace for the peripheral insertion of central venous catheters in infants
2014	HAYES, Inc.	Upright magnetic resonance imaging for diagnosis of spinal disorders
2014	NIHR Health Services and Delivery Research programme	A rapid synthesis of the evidence on interventions supporting self-management for people with long-term conditions: PRISMS - Practical systematic RevIew of Self-Management Support for long-term conditions
2014	Canadian Agency for Drugs and Technologies in Health (CADTH)	Electromagnetic interference between healthcare laser systems and sensitive electronic devices: safety and guidelines
2014	HTA Unit, University of Calgary	Best practices in the management of behavioural and psychological symptoms of dementia in residents of long-term care facilities in Alberta
2014	Malaysian Health Technology Assessment (MaHTAS)	Extracorporeal Shockwave Myocardial Revascularization (ESMR)
2014	National Institute for Health and Care Excellence (NICE)	Nalmefene for reducing alcohol consumption in people with alcohol dependence. NICE technology appraisal guidance 325
2014	NIHR Horizon Scanning Centre (NIHR HSC)	Interferon beta-1a (Traumakine) for acute respiratory distress syndrome – first line
2014	HAYES, Inc.	CBJ test GTE report with evidence table
2014	NIHR Health Services and Delivery Research programme	Reducing Care Utilisation through Self-management Interventions (RECURSIVE): a systematic review and meta-analysis
2014	Canadian Agency for Drugs and Technologies in Health (CADTH)	Radiation emissions from computed tomography: a review of the risk of cancer and guidelines
2014	Malaysian Health Technology Assessment (MaHTAS)	T.SPOT.TB assay – an update
2014	National Institute for Health and Care Excellence (NICE)	Imatinib for the adjuvant treatment of gastrointestinal stromal tumours. NICE technology appraisal guidance 326
2014	National Institute for Health and Care Excellence (NICE)	Atrial fibrillation and heart valve disease: self-monitoring coagulation status using point-of-care coagulometers (the CoaguChek XS system). NICE diagnostics guidance 14
2014	NIHR Horizon Scanning Centre (NIHR HSC)	Mepolizumab for severe refractory eosinophilic asthma – first line
2014	HAYES, Inc.	CHARGE syndrome
2014	NIHR Health Services and Delivery Research programme	Learning for the NHS on procurement and supply chain management: a rapid evidence assessment
2014	Canadian Agency for Drugs and Technologies in Health (CADTH)	Magnetic resonance imaging for patients with surgically implanted devices: safety and guidelines
2014	Malaysian Health Technology Assessment (MaHTAS)	Computer assisted surgery for unicondylar and total knee replacement
2014	National Institute for Health and Care Excellence (NICE)	Dabigatran etexilate for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism. NICE technology appraisal guidance 327
2014	NIHR Horizon Scanning Centre (NIHR HSC)	Brodalumab for moderate to severe plaque psoriasis
2014	HAYES, Inc.	Corus CAD
2014	Unidad de Evaluacion de Tecnologias Sanitarias (UETS)	[Review of positron emission tomography (PET) indications. Appropriate use criteria]
2014	Canadian Agency for Drugs and Technologies in Health (CADTH)	Waterless wipes for chemical eye injuries: clinical effectiveness
2014	Malaysian Health Technology Assessment (MaHTAS)	Acupuncture for chemotherapy-induced nausea and vomiting in cancer patients
2014	Andalusian Health Technology Assessment Area (AETSA)	Digital tomosynthesis in breast cancer. Systematic Review
2014	Scottish Health Technologies Group (SHTG)	What is the clinical and cost effectiveness of treatment with renal denervation for patients with resistant hypertension?
2014	Agency for Healthcare Research and Quality (AHRQ)	Prevention of dental caries in children younger than 5 years old: systematic review to update the U.S. Preventive Services Task Force Recommendation
2014	HAYES, Inc.	Molecular/cytogenetic testing for diagnosis and prognosis in primary/de novo acute myeloid leukemia (AML)
2014	Unidad de Evaluacion de Tecnologias Sanitarias (UETS)	[Comparative effectiveness of conservative treatment of breast cancer with brachytherapy and external beam radiation]
2014	Canadian Agency for Drugs and Technologies in Health (CADTH)	Fentanyl transdermal patches in palliative care: clinical effectiveness, safety, and guidelines
2014	Andalusian Health Technology Assessment Area (AETSA)	Anti TNF alpha drugs for adults with moderate to severe non fistulizing active Chron's disease.